• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.基础与催化创新:抗菌药物耐药性领导小组统计与数据管理中心
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S18-S23. doi: 10.1093/cid/ciw827.
2
Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.通过整合传统与创新方法引领抗菌实验室研究:抗菌耐药性领导小组实验室中心
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S13-S17. doi: 10.1093/cid/ciw826.
3
Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.掩人耳目:抗菌耐药性领导组的科学领导力、临床运营、统计和数据管理以及实验室中心。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S288-S294. doi: 10.1093/cid/ciad529.
4
Antibacterial resistance leadership group: open for business.抗菌耐药性领导小组:开始运作。
Clin Infect Dis. 2014 Jun;58(11):1571-6. doi: 10.1093/cid/ciu132. Epub 2014 Mar 6.
5
The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.抗菌耐药性领导组织:科学进展与未来方向。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S279-S287. doi: 10.1093/cid/ciad475.
6
Antibacterial Resistance Leadership Group 2.0: Back to Business.抗菌药物耐药性问题治理全球领导人联盟 2.0:重回正轨。
Clin Infect Dis. 2021 Aug 16;73(4):730-739. doi: 10.1093/cid/ciab141.
7
The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group.管理在应对抗菌药物耐药性中的作用:抗菌药物耐药性领导小组的管理与感染控制委员会
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S36-S40. doi: 10.1093/cid/ciw830.
8
The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.抗菌药物耐药性领导小组:进展报告与工作进展
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824.
9
Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group.将概念转化为临床试验并创建多中心网络:抗菌耐药性领导小组的领导与运营中心
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S8-S12. doi: 10.1093/cid/ciw825.
10
The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.未来已不再是过去的样子……旧的不去……新的更好:抗菌耐药性领导集团创新。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S321-S330. doi: 10.1093/cid/ciad538.

引用本文的文献

1
Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.掩人耳目:抗菌耐药性领导组的科学领导力、临床运营、统计和数据管理以及实验室中心。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S288-S294. doi: 10.1093/cid/ciad529.
2
Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.推进诊断技术以应对抗菌药物耐药性:抗菌药物耐药性领导小组诊断与设备委员会
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S41-S47. doi: 10.1093/cid/ciw831.
3
Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.革兰氏阴性菌感染:抗菌药物耐药性领导小组的研究重点、成果及未来方向
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S30-S35. doi: 10.1093/cid/ciw829.
4
Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.革兰氏阳性菌感染:抗菌药物耐药性领导小组的研究重点、成果及未来方向
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S24-S29. doi: 10.1093/cid/ciw828.
5
Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.通过整合传统与创新方法引领抗菌实验室研究:抗菌耐药性领导小组实验室中心
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S13-S17. doi: 10.1093/cid/ciw826.
6
The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.抗菌药物耐药性领导小组:进展报告与工作进展
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824.

本文引用的文献

1
Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?在耐药病原体环境中评估抗感染药物:我们能否使用外部对照?
Stat Commun Infect Dis. 2017;9(1). doi: 10.1515/scid-2016-0003. Epub 2017 Mar 14.
2
Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.利用结果分析患者而非利用患者分析结果:迈向效益-风险评估实用主义的一步。
Stat Biopharm Res. 2016;8(4):386-393. doi: 10.1080/19466315.2016.1207561. Epub 2016 Dec 6.
3
Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.推进诊断技术以应对抗菌药物耐药性:抗菌药物耐药性领导小组诊断与设备委员会
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S41-S47. doi: 10.1093/cid/ciw831.
4
The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group.管理在应对抗菌药物耐药性中的作用:抗菌药物耐药性领导小组的管理与感染控制委员会
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S36-S40. doi: 10.1093/cid/ciw830.
5
Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.通过整合传统与创新方法引领抗菌实验室研究:抗菌耐药性领导小组实验室中心
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S13-S17. doi: 10.1093/cid/ciw826.
6
Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.为抗生素治疗决策提供信息:评估快速分子诊断方法以确定不动杆菌属对碳青霉烯类药物的敏感性和耐药性(PRIMERS III研究)
J Clin Microbiol. 2016 Dec 28;55(1):134-144. doi: 10.1128/JCM.01524-16. Print 2017 Jan.
7
Comparing diagnostic tests on benefit-risk.比较诊断试验的获益-风险。
J Biopharm Stat. 2016;26(6):1083-1097. doi: 10.1080/10543406.2016.1226335. Epub 2016 Aug 22.
8
Methods and issues in studies of CRE.耐碳青霉烯肠杆菌研究中的方法和问题。
Virulence. 2017 May 19;8(4):453-459. doi: 10.1080/21505594.2016.1213473. Epub 2016 Jul 28.
9
Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME).诊断方法的获益-风险评估:一个框架(BED-FRAME)
Clin Infect Dis. 2016 Sep 15;63(6):812-7. doi: 10.1093/cid/ciw329. Epub 2016 May 18.
10
Comment: Fundamentals and Innovation in Antibiotic Trials.评论:抗生素试验的基本原理与创新
Stat Biopharm Res. 2015;7(4):331-336. doi: 10.1080/19466315.2015.1094406. Epub 2015 Dec 17.

基础与催化创新:抗菌药物耐药性领导小组统计与数据管理中心

Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

作者信息

Huvane Jacqueline, Komarow Lauren, Hill Carol, Tran Thuy Tien T, Pereira Carol, Rosenkranz Susan L, Finnemeyer Matt, Earley Michelle, Jiang Hongyu Jeanne, Wang Rui, Lok Judith, Evans Scott R

机构信息

Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.

Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health.

出版信息

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S18-S23. doi: 10.1093/cid/ciw827.

DOI:10.1093/cid/ciw827
PMID:28350899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5848245/
Abstract

The Statistical and Data Management Center (SDMC) provides the Antibacterial Resistance Leadership Group (ARLG) with statistical and data management expertise to advance the ARLG research agenda. The SDMC is active at all stages of a study, including design; data collection and monitoring; data analyses and archival; and publication of study results. The SDMC enhances the scientific integrity of ARLG studies through the development and implementation of innovative and practical statistical methodologies and by educating research colleagues regarding the application of clinical trial fundamentals. This article summarizes the challenges and roles, as well as the innovative contributions in the design, monitoring, and analyses of clinical trials and diagnostic studies, of the ARLG SDMC.

摘要

统计与数据管理中心(SDMC)为抗菌药物耐药性领导小组(ARLG)提供统计和数据管理专业知识,以推进ARLG的研究议程。SDMC在研究的各个阶段都发挥着积极作用,包括设计、数据收集与监测、数据分析与存档以及研究结果的发表。SDMC通过开发和实施创新实用的统计方法,并就临床试验基本原理的应用对研究同事进行培训,提高了ARLG研究的科学完整性。本文总结了ARLG SDMC在临床试验和诊断研究的设计、监测及分析中的挑战与作用,以及创新贡献。